Dienogest León Farma: Uses, Dosage & Side Effects

What Is Dienogest León Farma and What Is It Used For?

Dienogest León Farma belongs to a class of hormonal medications known as progestogens (also called progestins). Specifically, dienogest is classified as a fourth-generation progestogen, which means it was developed more recently than earlier progestins and has been refined to offer a more targeted therapeutic profile. Unlike many older progestogens that were designed primarily for contraception or hormone replacement therapy, dienogest at the 2 mg dose was specifically developed and clinically tested for the treatment of endometriosis.

Endometriosis is a chronic, estrogen-dependent gynecological condition that affects approximately 10% of women of reproductive age worldwide, representing an estimated 190 million women globally according to the World Health Organization. In endometriosis, tissue that is histologically similar to the endometrium (the lining of the uterus) is found growing outside the uterine cavity, most commonly on the ovaries, fallopian tubes, peritoneum, uterosacral ligaments, and rectovaginal septum. Less commonly, endometriotic implants can be found on the bowel, bladder, diaphragm, or even in distant locations such as the lungs. These ectopic endometrial implants respond to hormonal fluctuations during the menstrual cycle, undergoing proliferation, secretion, and shedding, which triggers a chronic inflammatory response that causes pain, scarring, and adhesion formation.

The cardinal symptoms of endometriosis include dysmenorrhea (painful periods), chronic pelvic pain, dyspareunia (pain during sexual intercourse), dyschezia (painful bowel movements), and dysuria (painful urination). Many women also experience fatigue, bloating, and gastrointestinal symptoms. Endometriosis is a leading cause of subfertility, with approximately 30–50% of affected women experiencing difficulty conceiving. The disease has a profound impact on quality of life, affecting physical functioning, emotional well-being, social relationships, and work productivity.

Dienogest exerts its therapeutic effects in endometriosis through a combination of complementary mechanisms that distinguish it from other hormonal treatments:

• Local anti-estrogenic effect: Dienogest suppresses the activity of two key enzymes involved in local estrogen production within endometriotic tissue: aromatase and 17-beta-hydroxysteroid dehydrogenase type 1. By reducing local estradiol concentrations at the site of endometriotic implants, dienogest deprives the lesions of the estrogenic stimulation they require for growth and maintenance, without causing the severe systemic hypoestrogenic effects seen with GnRH agonists.
• Antiproliferative effect: Dienogest directly inhibits the proliferation of endometriotic stromal and epithelial cells through multiple intracellular signaling pathways, including inhibition of the PI3K/Akt and ERK1/2 pathways. This leads to reduced growth and eventual regression of endometriotic lesions.
• Anti-inflammatory effect: Dienogest suppresses the production of pro-inflammatory cytokines (such as interleukin-6, interleukin-8, and tumor necrosis factor-alpha) and prostaglandins within endometriotic tissue. It also inhibits nuclear factor-kappa B (NF-kB) signaling, a key regulator of inflammatory gene expression. These anti-inflammatory effects contribute to pain relief and reduction of the inflammatory microenvironment that sustains endometriotic lesions.
• Anti-angiogenic effect: Dienogest reduces the formation of new blood vessels (angiogenesis) within endometriotic lesions by suppressing vascular endothelial growth factor (VEGF) expression. This limits the blood supply to endometriotic implants, contributing to lesion regression.
• Moderate suppression of ovulation: At the 2 mg daily dose, dienogest partially suppresses ovarian function and inhibits ovulation in most women, although this effect is not sufficiently consistent to provide reliable contraception. The partial suppression of ovarian estradiol production contributes to the overall therapeutic effect.

The clinical efficacy of dienogest 2 mg in endometriosis has been established in several pivotal clinical trials. In a landmark 24-week, randomized, double-blind, active-controlled study comparing dienogest 2 mg daily with leuprorelin acetate depot (a GnRH agonist) in 252 women with laparoscopically confirmed endometriosis, dienogest demonstrated non-inferior efficacy in reducing endometriosis-associated pelvic pain as measured by the visual analogue scale (VAS). Both treatments produced clinically meaningful and statistically significant reductions in pain scores from baseline. A subsequent open-label extension study demonstrated sustained efficacy of dienogest over 53 weeks of continuous treatment, with progressive improvement in pain scores over time.

Additional clinical trials have confirmed the efficacy of dienogest across various endpoints, including reduction in dysmenorrhea, non-menstrual pelvic pain, and dyspareunia. Endoscopic studies have shown that dienogest treatment leads to regression of endometriotic lesions, with a significant proportion of patients demonstrating improvement in their revised American Fertility Society (rAFS) classification scores after 24 weeks of treatment.

What Should You Know Before Taking Dienogest León Farma?

Contraindications

Dienogest León Farma must not be used in the following circumstances:

• Active venous thromboembolic disorder: Women with current deep vein thrombosis (DVT) or pulmonary embolism (PE) must not take dienogest. Progestogens may influence blood coagulation, and active thromboembolic disease is an absolute contraindication.
• Arterial and cardiovascular disease: Dienogest is contraindicated in women with current or recent arterial thromboembolic disease, including ischemic heart disease (angina, myocardial infarction) or cerebrovascular disease (stroke, transient ischemic attack).
• Diabetes mellitus with vascular complications: Women with diabetes complicated by vascular involvement (retinopathy, nephropathy, neuropathy) should not use dienogest due to the increased cardiovascular risk.
• Severe hepatic disease: Dienogest is metabolized by the liver and must not be used in women with severe liver disease, including hepatic tumors (benign or malignant, current or history), or when liver function tests remain abnormal. Treatment may be initiated once liver function values have normalized and the liver condition has resolved.
• Known or suspected sex hormone-dependent malignancies: Since dienogest is a progestogen, it must not be used in women with known or suspected progestogen-sensitive malignancies, such as certain types of breast cancer or endometrial cancer.
• Undiagnosed vaginal bleeding: Any abnormal genital bleeding that has not been medically evaluated is a contraindication. The cause of the bleeding must be established before starting dienogest therapy.
• Hypersensitivity: Known allergy to dienogest or any of the tablet excipients (including lactose monohydrate, microcrystalline cellulose, magnesium stearate, povidone, crospovidone, and talc).

Warnings and Precautions

Before starting dienogest, discuss the following with your doctor:

• Thromboembolic risk: Although the risk appears lower than with combined hormonal contraceptives, dienogest may slightly increase the risk of venous thromboembolism. Risk factors that should be carefully evaluated include obesity (BMI > 30), recent surgery or prolonged immobilization, a personal or family history of thromboembolic events, smoking, and increasing age. If you develop symptoms suggestive of thrombosis (leg swelling, sudden chest pain, difficulty breathing), seek immediate medical attention.
• Bone mineral density: Long-term use of dienogest may be associated with a modest reduction in bone mineral density due to its mild anti-estrogenic effects. However, clinical studies of up to 15 months duration have shown that bone mineral density changes with dienogest are significantly smaller than those observed with GnRH agonists, and bone density tends to recover after discontinuation. Your doctor may consider monitoring bone mineral density if you have additional risk factors for osteoporosis.
• Bleeding pattern changes: Dienogest frequently alters menstrual bleeding patterns. Irregular vaginal bleeding (spotting, breakthrough bleeding, prolonged bleeding) is common, especially during the first months of treatment. Some women may develop amenorrhea (absence of periods). These changes are expected pharmacological effects and are generally not harmful, but any persistent or heavy bleeding should be reported to your doctor.
• Depression and mood changes: Progestogens, including dienogest, may affect mood. Some women experience depressed mood, mood swings, irritability, or anxiety during treatment. If you have a history of depression or other psychiatric conditions, discuss this with your doctor before starting dienogest. Contact your doctor promptly if you experience significant mood changes.
• Effect on glucose metabolism: Dienogest may have a minor influence on glucose tolerance and insulin sensitivity. Women with diabetes should monitor their blood glucose levels more closely when starting dienogest treatment and discuss any necessary adjustments to antidiabetic medication with their doctor.

Pregnancy and Breastfeeding

Dienogest must not be used during pregnancy. There is no therapeutic indication for dienogest during pregnancy, and animal studies have shown reproductive toxicity at doses exceeding the recommended human dose. If pregnancy occurs during dienogest treatment, the medication should be discontinued immediately. Clinical data from inadvertent exposure during early pregnancy have not indicated an increased risk of congenital malformations, but the evidence is limited.

Dienogest is excreted in breast milk in small amounts. Because of the potential effects on the nursing infant, dienogest is not recommended during breastfeeding. If treatment is considered essential, the decision to continue breastfeeding or to discontinue dienogest should be made after careful consideration of the benefits and risks, in consultation with your doctor.

After discontinuation of dienogest, ovulation typically returns within one to two menstrual cycles. Fertility studies have shown that dienogest does not impair long-term fertility, and pregnancy rates following discontinuation are comparable to those expected in the general population of women with endometriosis. Many women planning pregnancy are advised to stop dienogest and try to conceive during the initial period after discontinuation, when endometriosis symptoms may still be reduced.

Driving and Operating Machinery

Dienogest has no known effect on the ability to drive or operate machinery. No specific studies have been conducted, but based on the pharmacological profile and clinical experience, impairment is not expected. However, if you experience dizziness or difficulty concentrating (which are uncommon side effects), exercise caution when driving or operating machinery until you know how dienogest affects you.

How Does Dienogest León Farma Interact with Other Drugs?

Understanding potential drug interactions with dienogest is important for ensuring both the efficacy and safety of your treatment. Dienogest is predominantly metabolized in the liver by the cytochrome P450 enzyme CYP3A4, which is responsible for the metabolism of a large proportion of clinically used drugs. This metabolic pathway creates the potential for pharmacokinetic interactions with other medications that affect CYP3A4 activity.

The following table summarizes the most clinically relevant drug interactions with dienogest:

Major Interactions

The most clinically significant interaction involves CYP3A4 inducers, particularly rifampicin (rifampin). Rifampicin is one of the most potent known inducers of CYP3A4 and can increase the metabolic clearance of dienogest dramatically, reducing its plasma concentrations by approximately 83% based on interaction studies with similar progestogens. This degree of reduction would be expected to substantially compromise the therapeutic efficacy of dienogest. Other potent CYP3A4 inducers, including carbamazepine, phenytoin, phenobarbital, and primidone (antiepileptic drugs), as well as the HIV medication efavirenz and the herbal supplement St. John’s Wort (Hypericum perforatum), can have similar effects.

If you require treatment with a potent CYP3A4 inducer, discuss with your doctor whether an alternative to either dienogest or the interacting medication is available. If concurrent use is unavoidable, your doctor should be aware that the efficacy of dienogest may be significantly reduced, and closer monitoring of endometriosis symptoms is warranted.

Minor Interactions

CYP3A4 inhibitors, such as azole antifungals (ketoconazole, itraconazole, voriconazole), macrolide antibiotics (erythromycin, clarithromycin), protease inhibitors (ritonavir, nelfinavir), and grapefruit juice, can inhibit the metabolism of dienogest, leading to increased plasma levels. While moderately elevated dienogest levels are generally well tolerated, increased exposure may heighten the risk or severity of dose-dependent side effects. If you are prescribed a CYP3A4 inhibitor, your doctor may wish to monitor you for side effects more closely.

It is important to note that dienogest itself does not significantly induce or inhibit CYP enzymes at therapeutic doses, so it is unlikely to affect the metabolism of other drugs you are taking. However, always inform your doctor or pharmacist about all medications, including over-the-counter drugs, herbal supplements, and vitamins, to ensure comprehensive monitoring.

What Is the Correct Dosage of Dienogest León Farma?

Dienogest León Farma should always be used exactly as prescribed by your doctor. The standard dosing regimen is straightforward: one tablet of 2 mg taken by mouth once every day, continuously, without any breaks or pill-free intervals. Unlike combined oral contraceptives, which are typically taken in 21- or 24-day active cycles followed by hormone-free intervals, dienogest for endometriosis is taken every single day without interruption.

Adults

Treatment with dienogest can be started on any day of the menstrual cycle. If you are switching from another hormonal treatment for endometriosis or from a hormonal contraceptive, dienogest can be started immediately after discontinuation of the previous medication. There is no need to wait for a withdrawal bleed before beginning dienogest.

The tablet should be taken at approximately the same time each day to maintain consistent plasma levels of the drug. It can be taken with or without food, as food does not significantly affect the absorption of dienogest. The tablet should be swallowed whole with a glass of water. Continue taking the tablet every day, even if vaginal bleeding occurs. When the current pack of tablets is finished, start the next pack immediately on the following day without any break.

Children and Adolescents

Dienogest León Farma is not recommended for use in children who have not yet reached menarche (their first menstrual period). The safety and efficacy of dienogest have been studied in adolescent women (12–18 years) with endometriosis in open-label clinical trials, and the results suggest a similar safety and efficacy profile as in adult women. However, the prescribing decision should be made on an individual basis by the treating gynecologist, taking into account the severity of symptoms and the impact on the adolescent’s quality of life. Special consideration should be given to the potential effects on bone mineral density in this age group, as adolescence is a critical period for bone accrual.

Elderly Patients

There is no relevant indication for the use of dienogest in postmenopausal women. Endometriosis is an estrogen-dependent condition that primarily affects women of reproductive age, and the disease typically regresses after menopause. Dienogest has not been studied in the elderly population.

Missed Dose

If you forget to take a tablet, or if you experience vomiting or diarrhea within 3–4 hours after taking a tablet (which could impair absorption), take the missed or replacement tablet as soon as you remember, and then continue taking the next tablet at your usual time the following day. Do not take a double dose to compensate for a missed tablet. If you have missed one or more tablets and have not yet had a menstrual bleed during that cycle, consider the possibility of pregnancy (since dienogest does not provide reliable contraception) and take a pregnancy test before resuming treatment.

Consistent daily dosing is important for maintaining the therapeutic effect of dienogest. Setting a daily alarm on your phone or associating tablet-taking with a routine daily activity (such as brushing your teeth in the evening) can help you remember to take your medication on time.

Overdose

There have been no reports of serious adverse effects from overdose with dienogest. In the event of accidental ingestion of multiple tablets, symptoms may include nausea, vomiting, and possibly vaginal bleeding or spotting. There is no specific antidote for dienogest overdose. Treatment should be symptomatic and supportive. If you have taken more dienogest than prescribed, contact your doctor, pharmacist, or poison control center for advice.

What Are the Side Effects of Dienogest León Farma?

Like all medicines, dienogest can cause side effects, although not everyone who takes it will experience them. The side effects described below are based on data from clinical trials involving more than 4,000 women treated with dienogest 2 mg for endometriosis, as well as post-marketing surveillance data. Understanding the potential side effects and their frequencies can help you and your doctor make informed decisions about your treatment.

The most frequently reported side effect is a change in menstrual bleeding patterns, which is an expected pharmacological consequence of the progestogenic activity of dienogest. During the first few months of treatment, many women experience irregular vaginal bleeding (spotting, breakthrough bleeding, or prolonged bleeding). Over time, the frequency and intensity of bleeding episodes typically decrease, and approximately 20–30% of women develop amenorrhea (complete absence of menstrual bleeding) with continued use. These bleeding pattern changes, while sometimes inconvenient, are not harmful and do not indicate a medical problem in most cases.

It is important to understand that many of the common side effects of dienogest, particularly headache, breast tenderness, mood changes, and acne, tend to be most noticeable during the first three to six months of treatment and often diminish in frequency and severity with continued use. This pattern of initial side effects followed by improvement is consistent with the body’s adaptation to the altered hormonal environment created by dienogest.

Weight gain is reported as a very common side effect, but the magnitude is generally modest. In clinical trials, the mean weight gain over 24 weeks of treatment was approximately 1.2 kg. Some women may experience more noticeable weight changes, while others may not gain any weight. Maintaining a balanced diet and regular physical activity during treatment can help manage weight.

Ovarian cysts are a common side effect and are typically functional cysts that develop as a consequence of the partial suppression of ovarian function by dienogest. These cysts are usually small, asymptomatic, and resolve spontaneously without treatment. In rare cases, larger cysts may cause pelvic discomfort and may require monitoring with ultrasound. Your doctor will advise you on the management of any ovarian cysts that are detected.

Depressed mood and mood changes deserve particular attention. In clinical trials, depressed mood was reported by approximately 5–6% of women taking dienogest. While most cases were mild and did not require treatment discontinuation, a small proportion of women may experience more significant mood disturbances. If you notice persistent low mood, loss of interest in daily activities, changes in sleep patterns, or thoughts of self-harm, contact your doctor immediately. Women with a history of depression should be monitored closely during treatment.

How Should You Store Dienogest León Farma?

Proper storage of Dienogest León Farma is important to ensure the quality, efficacy, and safety of your medication throughout its shelf life. As an oral solid dosage form (tablet), dienogest is generally more stable than liquid formulations or biologics, but it still requires appropriate storage conditions to maintain its pharmaceutical properties.

Follow these storage guidelines:

• Temperature: Store at room temperature, not exceeding 30 °C (86 °F). Avoid exposure to excessive heat. Do not store the tablets in direct sunlight or near heat sources (radiators, hot water pipes, or car dashboards in summer).
• Moisture protection: Keep the tablets in the original blister packaging until immediately before taking each dose. The blister packaging provides protection against moisture, which can degrade the medication. Do not transfer the tablets to a pill organizer for extended periods.
• Light protection: While the original packaging provides some light protection, store the medication in a location that is not exposed to direct sunlight.
• Keep out of reach of children: Store the medication in a secure location where children cannot access it. Even a single tablet could have hormonal effects in a child.
• Check expiration date: Do not use the tablets after the expiration date printed on the blister and carton packaging. The expiration date refers to the last day of the indicated month. Expired medication should be returned to a pharmacy for proper disposal.
• Do not freeze: While accidental brief freezing is unlikely to damage tablets, it is not recommended. Follow the stated storage temperature range.
• Disposal: Do not dispose of unused or expired tablets in household waste or via the sewage system. Return any unused medication to a pharmacy for environmentally safe disposal.

When traveling, keep the medication in your hand luggage rather than checked baggage to avoid extreme temperatures. Carry the tablets in their original packaging, which includes the product name, strength, and expiration date, as this may be requested at customs or border checks.

What Does Dienogest León Farma Contain?

Understanding the full composition of your medication is important, particularly if you have known allergies, intolerances, or dietary restrictions that may interact with pharmaceutical excipients.

Active Ingredient

The active substance is dienogest, a synthetic progestogen derived from 19-nortestosterone. Each tablet contains exactly 2 mg of dienogest. Chemically, dienogest is 17-alpha-cyanomethyl-17-beta-hydroxyestra-4,9(10)-dien-3-one (molecular formula: C₂₀H₂₅NO₂; molecular weight: 311.4 g/mol). Unlike many other 19-nortestosterone derivatives, dienogest has a unique hybrid structure that combines the pharmacological properties of 19-nortestosterone progestins (strong progestogenic effect on the endometrium) with some characteristics of progesterone derivatives (anti-androgenic rather than androgenic activity).

Inactive Ingredients (Excipients)

Appearance and Pack Sizes

Dienogest León Farma tablets are white to off-white, round, uncoated tablets. They are supplied in blister packs. Available pack sizes may vary by country and market but typically include packs of 28 tablets (one month’s supply) or 84 tablets (three months’ supply). Not all pack sizes may be available in every market.

Marketing Authorization Holder

The marketing authorization for Dienogest León Farma is held by Laboratorios León Farma S.A., a pharmaceutical company based in Spain. The medication is a generic equivalent of the originator product Visanne (manufactured by Bayer), containing the same active ingredient, strength, dosage form, and route of administration. Generic medications undergo rigorous bioequivalence testing to ensure they are therapeutically equivalent to the originator product.